Diasorin SpAMIL:DIA +3.13%67 ROA % is 2.59% as of Dec. 2025, which is 82% below its 10-year median of 14.08. GuruFocus rates MIL:DIA with a GF Score™ of 67/100 and a GF Value™ of €90.07 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 74.88% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Diasorin SpA's annualizedNet Income for the quarter that ended in Dec. 2025 was €74 Mil.
Diasorin SpA's average Total Assets over the quarter that ended in Dec. 2025 was €2,873 Mil. Therefore, Diasorin SpA's annualized ROA % for the quarter that ended in Dec. 2025 was 2.59%.
The historical rank and industry rank for Diasorin SpA's ROA % or its related term are showing as below:
MIL:DIA'
s ROA % Range Over the Past 10 Years
Min: 4.71 Med: 14.08 Max: 21.46
Current: 4.71
During the past 13 years, Diasorin SpA's highest ROA % was 21.46%. The lowest was 4.71%. And the median was 14.08%.
MIL:DIA's ROA % is ranked better than 74.88% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.87
vs MIL:DIA: 4.71
Diasorin SpA (MIL:DIA) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Diasorin SpA ROA % Related Terms
Diasorin SpA ROA % Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Diasorin SpA's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA ROA % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's ROA % distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Diasorin SpA (MIL:DIA) has a ROA % of 2.59% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Diasorin SpA and its competitors. This is 82% below median its historical median of 14.08. Over the past decade, Diasorin SpA's ROA % has ranged from 4.71 to 21.46. According to the industry distribution chart, Diasorin SpA ranks #54 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 25.1%.
Is Diasorin SpA's ROA % too high?
Diasorin SpA's current ROA % of 2.59% is 82% below median its 10-year median of 14.08. Over the past 10 years, this metric has ranged from a low of 4.71 to a high of 21.46. Based on the distribution chart, Diasorin SpA ranks #54 out of 215 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's ROA % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #54 out of 215 companies for ROA %. This puts Diasorin SpA in the upper half of its industry. Historically, Diasorin SpA's own ROA % has ranged from 4.71 to 21.46 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Diagnostics & Research company?
A good ROA % depends on the Medical Diagnostics & Research industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Diasorin SpA and its competitors. Diasorin SpA's current ROA % is 2.59%, which is 82% below median its own 10-year median of 14.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (MIL:DIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.07, compared to a current price of €66.48 — trading 26.2% below its estimated fair value. The current ROA % is 2.59%, which is 82% below median its 10-year median of 14.08. Diasorin SpA's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Diasorin SpA (MIL:DIA), the current ROA % is 2.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (MIL:DIA) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €66.48 is trading 26.2% below its estimated GF Value™ of €90.07.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for MIL:DIA:
ROA %: 2.59% (82% below median its 10-year median of 14.08)
GF Value™: €90.07 vs. price of €66.48 (26.2% below fair value)
No single metric tells the full story. See the MIL:DIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
67GF Score
Get the complete analysis for MIL:DIA
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:DIA has been successfully added to your 
